Literature DB >> 23978325

High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia.

Swetha Vijayaraghavan1, Walter Maetzler2, Matthias Reimold3, Christina Unger Lithner1, Inga Liepelt-Scarfone2, Daniela Berg2, Taher Darreh-Shori4.   

Abstract

Apolipoprotein E ε4 allele (APOE ε4) increases the apolipoprotein E (apoE) protein levels in Alzheimer's disease (AD) cerebrospinal fluid (CSF). Thus, we hypothesized that apoE levels were also associated with the APOE genotype, and amyloid-β (Aβ)-associated clinical, functional, and imaging parameters in patients with Lewy body-associated disorders (LBD). Indeed, similar to AD, patients with LBD displayed high CSF apoE levels (greatest in patients with dementia with LBD), and this was linked to APOE ε4. High CSF apoE protein correlated positively with CSF soluble amyloid precursor protein, total tau, and cortical and striatal Pittsburgh compound B retention; and correlated negatively with CSF Aβ42, cognitive tests scores, and glucose uptake ratio in the temporal and parietal cortices. APOE ε4-triggered accumulation of apoE in CSF is related to Aβ-associated clinical and functional imaging parameters in LBD. Accordingly, therapeutic strategies aimed at reducing apoE levels in the brain should be explored not only in AD but also in LBD, particularly when accompanied with dementia.
Copyright © 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-β; Apolipoprotein E; Cerebrospinal fluid; Dementia with Lewy bodies; Fluorodeoxyglucose–positron emission tomography; Lewy body-associated disorders; Pittsburgh compound B–positron emission tomography; Positron emission tomography

Mesh:

Substances:

Year:  2013        PMID: 23978325     DOI: 10.1016/j.jalz.2013.03.010

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  8 in total

1.  CSF Apo-E levels associate with cognitive decline and MRI changes.

Authors:  Jon B Toledo; Xiao Da; Michael W Weiner; David A Wolk; Sharon X Xie; Steven E Arnold; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-01-03       Impact factor: 17.088

2.  The synergistic risk effect of apolipoprotein ε4 and DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B) haplotype for Alzheimer's disease.

Authors:  Cíntia Monique Boschmann Ens de Bem; Julio Carlos Pezzi; Ericksen Mielle Borba; Marcia Lorena Fagundes Chaves; Fabiana Michelsen de Andrade; Marilu Fiegenbaum; Analuiza Camozzato
Journal:  Mol Biol Rep       Date:  2016-05-17       Impact factor: 2.316

Review 3.  The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease.

Authors:  Dilek Inekci; Ditte Svendsen Jonesco; Sophie Kennard; Morten Asser Karsdal; Kim Henriksen
Journal:  Front Neurol       Date:  2015-05-11       Impact factor: 4.003

4.  Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort.

Authors:  Guro Berge; Sigrid B Sando; Arvid Rongve; Dag Aarsland; Linda R White
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-03-17       Impact factor: 10.154

5.  Homomeric and Heteromeric Aβ Species Exist in Human Brain and CSF Regardless of Alzheimer's Disease Status and Risk Genotype.

Authors:  Erica Lana; Anna Gellerbring; Sabrina Jung; Agneta Nordberg; Christina Unger Lithner; Taher Darreh-Shori
Journal:  Front Mol Neurosci       Date:  2019-07-31       Impact factor: 5.639

6.  Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.

Authors:  Inger van Steenoven; Wiesje M van der Flier; Philip Scheltens; Charlotte E Teunissen; Afina W Lemstra
Journal:  Alzheimers Res Ther       Date:  2019-10-10       Impact factor: 6.982

7.  Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases.

Authors:  K Minta; G Brinkmalm; S Janelidze; S Sjödin; E Portelius; E Stomrud; H Zetterberg; K Blennow; O Hansson; U Andreasson
Journal:  Alzheimers Res Ther       Date:  2020-02-13       Impact factor: 6.982

8.  Amyloid-β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAβACs.

Authors:  Rajnish Kumar; Agneta Nordberg; Taher Darreh-Shori
Journal:  Brain       Date:  2015-11-02       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.